Skip to main content

Usana Health Sciences Value Stock - Dividend - Research Selection

Usana health sciences

ISIN: US90328M1071 , WKN: 923145

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

General

 

USANA Health Sciences, Inc., a Utah corporation, was founded in 1992 by Myron W. Wentz, Ph.D. We develop and manufacture high-quality, science-based nutritional and personal care products with a primary focus on promoting long-term health and reducing the risk of chronic degenerative disease. In so doing, we are committed to continuous product innovation and sound scientific research. We have operations in 19 markets worldwide, where we distribute and sell our products by way of direct selling. We have chosen this distribution method as we believe it is the most conducive to meeting our vision as a company, which is improving the overall health and nutrition of individuals and families around the world. Our net sales in fiscal year 2014 were $790.5 million, of which 81.8% were in markets outside of the United States. As a U.S.-based multi-national company with an expanding international presence, our operating results are sensitive to currency fluctuations, as well as economic and political conditions in markets throughout the world. Additionally, we are subject to the various laws and regulations in the United States, China, and the other markets in which we operate with respect to the products that we sell and to our method of distribution.

 

Our customer base comprises two types of customers: "Associates" and "Preferred Customers." Associates share in our company vision by acting as independent distributors of our products in addition to purchasing our products for their personal use. Preferred Customers purchase our products strictly for personal use and are not permitted to resell or to distribute the products. As of January 3, 2015, we had 349,000 active Associates and 81,000 active Preferred Customers worldwide.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


USANA's CellSentials Supplement Earns Independent Quality Seal

2026-03-24
USANA (NYSE:USNA), a global leader in cellular nutrition, today announced that its flagship CellSentials supplement has earned the prestigious ConsumerLab.com Seal of Approval. This highly respected third-party

EHC Stock: Do Valuation and Expansion Trends Support a Hold Strategy?

2026-03-16
EHC is expanding its inpatient rehab network and posting steady revenue and cash-flow growth, but Medicaid policy risks and higher debt remain concerns.

JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study

2026-03-16
J&J reports phase I study win for Erda-iDRS in NMIBC, showing strong response rates, durable control and manageable safety as mid-to-late-stage studies advance.

Cigna Stock Trades Below Industry P/E: Is It Worth Holding Now?

2026-03-13
CI trades below industry P/E as Evernorth growth, steady earnings beats and buybacks support outlook, though rising medical costs and debt remain key risks.

RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study

2026-03-13
Ultragenyx Pharmaceutical reports phase III success for DTX301 in OTC deficiency, lowering ammonia 18% compared to placebo and keeping levels normal through 36 weeks.

2 Profitable Stocks Worth Your Attention and 1 We Brush Off

2026-03-13
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".

RLMD Stock Surges 42% in a Week: Here's What You Should Know

2026-03-12
Relmada Therapeutics jumps 42% in a week after reporting encouraging efficacy and safety data from a mid-stage bladder cancer study of NDV-01, simultaneously sharing phase III plans.

USNA or ZTS: Which Is the Better Value Stock Right Now?

2026-03-12
USNA vs. ZTS: Which Stock Is the Better Value Option?

EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y

2026-03-10
Editas stock jumps 16% on reporting a narrower-than-expected Q4 loss and beating revenue estimates while advancing its EDIT-401 gene-editing candidate toward its first human study in 2026.

USANA Health (USNA) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

2026-03-10
USANA Health (USNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.